In one study, the novel PARPi fluzoparib plus apatinib, a VEGFR2 tyrosine kinase inhibitor, is oriented for patients with gBRCA-mutated HER2-negative metastatic BC (NCT04296370). This evidence concerns the gene KDR and breast cancer.